The mechanisms driving the loss of dopamine neurons in the brain of people with Parkinson’s disease are not well-understood. However, excess generation of reactive oxygen species (ROS),[1][2] inflammation, and mitochondrial dysfunction are common themes in the pathology.[3] Many of the supplements researched for their possible therapeutic effects in experimental models and in clinical trials affect one or more of these pathological mechanisms.[4][5]
The following supplements have been studied in people with Parkinson’s disease: